Davita Inc vs Invesco Ltd. — how do they compare? Davita Inc trades at $179.02 (market cap $11.38B), while Invesco Ltd. trades at $31.16 (market cap $13.85B). The key difference: Invesco Ltd. is the larger of the two by market cap, and Invesco Ltd. pays a 2.74% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | IVZ | |
|---|---|---|
Market Cap | $11.38B | $13.85B |
Sector | Health | Financials |
52-Week High | $240.96 | $32.01 |
52-Week Low | $103.87 | $20.67 |
Enterprise Value | $24.10B | $24.01B |
Dividend Yield | — | 2.74% |
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →